Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.51 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409043 | 0.88 | PTGER1 (0.48) | ESR1PTGER1POLBKMT2AKDM4C | |
| SCHEMBL4033560 | 0.84 | ESR1 (0.54) | ESR1MEN1POLBKMT2A | |
| SCHEMBL4032078 | 0.83 | ESR1 (0.57) | ESR1PTGER1MEN1KMT2A | |
| SCHEMBL4029086 | 0.81 | ESR1 (0.57) | ESR1 | |
| SCHEMBL4028980 | 0.81 | ESR1 (0.57) | ESR1 | |
| SCHEMBL4027878 | 0.80 | ESR1 (0.63) | ESR1KMT2AKDM4ETSHRHSD17B10 | |
| SCHEMBL4030264 | 0.80 | NAMPT (0.53) | ESR1DHODHNAMPTPTGER1POLB | |
| SCHEMBL4033542 | 0.76 | ESR1 (0.57) | ESR1KMT2A | |
| SCHEMBL4035081 | 0.75 | ESR1 (0.57) | ESR1PTGER1MEN1KMT2A | |
| SCHEMBL4029205 | 0.73 | ESR1 (0.72) | ESR1MEN1KMT2AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885DHODH 4017/4885NAMPT 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.